Does fully closed‐loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta‐analysis of randomized controlled trials
Diabetic Medicine · 2024
DOI: 10.1111/dme.15196 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetic Medicine, 2024. Verfasst von Basma Ehab Amer und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Hypoglycemia, Hyperglycemia. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
This meta‐analysis investigated the efficacy and safety of fully closed‐loop automated insulin delivery (AID) in patients with type 2 diabetes. Materials and Methods We systemically searched PubMed, Scopus, Web of Science, and Cochrane Central from inception until April 26, 2023. We included randomized controlled trials (RCTs) comparing fully closed‐loop AID versus conventional insulin therapy. The outcomes were pooled as the mean difference (MD) and risk ratio with 95% confidence interval (CI) in the random effect model. Our primary outcome was the proportion of time in the target glucose range (5.6‐10 mmol/L, 3.9‐10 mmol/L, or 3.9‐8 mmol/L, depending on the study). Key secondary outcomes included the proportion of time spent in hyperglycaemia or hypoglycaemia.
Results
We included seven RCTs (three crossover and four parallel design), compromising 390 patients. Our analysis showed that compared to the control group, fully closed‐loop AID increased the proportion of time spent within the target glucose range by additional 337 min per 24 h (MD = 23.39%, 95% CI [16.64%, 30.14%], p < 0.01), additional 108 min overnight (MD = 22.40%, 95% CI [12.88%, 31.91%], p < 0.01), and additional 258 min during the daytime period (MD = 26.85%, 95% CI [21.06%, 32.63%], p < 0.01). Compared to the control group, the overall time in hyperglycaemia was shortened by 326 min per 24 h (MD = −22.67%, 95% CI [−30.87%, −14.46%], p < 0.01). There was no significant difference between the two groups in terms of overall, overnight, and daytime periods spent in hypoglycaemia.
Conclusions
Our meta‐analysis suggests that fully closed‐loop AID may improve glycaemic control in patients with type 2 diabetes, particularly for those with more challenging diabetes management. Further research is required to establish the feasibility of implementing these systems in clinical practice. [Correction added on 26 August 2023 after first online publication: Under Results, the first sentence “We included seven RCTs (three crossover and one parallel designs)” has been changed to “We included seven RCTs (three crossover and four parallel designs)”.]
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Research Group of Egypt, Negida Academy, Arlington, Massachusetts, USA.
- Faculty of Medicine, Benha University, Benha, Egypt.
- Faculty of Medicine, Alexandria University, Alexandria, Egypt.
- Faculty of Medicine, Tanta University, Tanta, Egypt.
- Faculty of Science, Cairo University, Cairo, Egypt.
ORCID-Profile: Basma Ehab Amer
Zitieren
APA
Amer, B. E., Yaqout, Y. E., Abozaid, A. M., Afifi, E., & Aboelkhier, M. M. (2024). Does fully closed‐loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta‐analysis of randomized controlled trials. Diabetic Medicine. https://doi.org/10.1111/dme.15196
Vancouver
Amer BE, Yaqout YE, Abozaid AM, Afifi E, Aboelkhier MM. Does fully closed‐loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta‐analysis of randomized controlled trials. Diabetic Medicine. 2024. doi:10.1111/dme.15196
BibTeX
@article{Amer2024,
author = {Amer, Basma Ehab and Yaqout, Yasmeen Essam and Abozaid, Ahmed Mohamed and Afifi, Eslam and Aboelkhier, Menna M},
title = {Does fully closed‐loop automated insulin delivery improve glycaemic control in patients with type 2 diabetes? A meta‐analysis of randomized controlled trials},
journal = {Diabetic Medicine},
year = {2024},
doi = {10.1111/dme.15196}
}
EUVIMED